A key step to deliver RNAi therapeutics to diverse cell types and tissues beyond the liver from the collaboration of ...

Orum Therapeutics ("Orum" or the "Company") (KRX: 475830), a public biotechnology company pioneering the field of ...

A novel polycyclic aromatic hydrocarbon derivative hole selective material (4PADNC) has been designed to optimize hole ...

Radionuclide drug conjugates (RDCs) have emerged as transformative agents that integrate diagnosis and therapy into a single ...

The combined Company will move forward as Decoy Therapeutics, Inc. and trade on the NASDAQ Stock Market under the ticker “DCOY” effective in ...

Researchers at the Johns Hopkins Kimmel Cancer Center’s Ludwig Center developed a new treatment that selectively targets ...

Learn more about whether Catalyst Pharmaceuticals, Inc. or Zymeworks Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Adding another potential wrinkle to the industry’s work with China is the Biosecure Act, a piece of China-targeting national ...

As 2025 comes to a close, the U.S. healthcare industry remains one of the most influential pillars of the market, driven by ...

Ipsen may be a recent entrant into the antibody-drug conjugate space, but the French biopharma is continuing to make up for lost time. | Ipsen may be a recent entrant into the antibody-drug conjugate ...

DESTINY-Endometrial02 is a phase 3 trial assessing T-DXd as an adjuvant treatment for HER2-expressing endometrial cancer, ...